A5076345342- Cervical Cancer and HPV Research
- Global Cancer Incidence and Screening
- Genital Health and Disease
- Hepatitis B Virus Studies
- Endometrial and Cervical Cancer Treatments
- Colorectal Cancer Screening and Detection
- Molecular Biology Techniques and Applications
- Reproductive tract infections research
- Colorectal and Anal Carcinomas
- Cancer-related molecular mechanisms research
- Cancer-related Molecular Pathways
- AI in cancer detection
- Reliability and Agreement in Measurement
- MicroRNA in disease regulation
- Ovarian cancer diagnosis and treatment
- Animal Virus Infections Studies
- Smoking Behavior and Cessation
- Multiple and Secondary Primary Cancers
- Head and Neck Cancer Studies
- School Health and Nursing Education
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Injury Epidemiology and Prevention
- Microbial infections and disease research
- Infectious Diseases and Mycology
Piedmont Reference Center for Epidemiology and Cancer Prevention
2014-2025
Sapienza University of Rome
2023
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino
1998-2020
Centre International de Recherche sur le Cancer
2014-2020
National Centre for Disease Prevention and Control
2007-2020
Massachusetts General Hospital
2016
John Wiley & Sons (United States)
2016
Hudson Institute
2016
Virginia Commonwealth University
2016
Mount Sinai Hospital
2016
European Guidelines for Quality Assurance in Cervical Cancer Screening have been initiated the Europe Against Programme. The first edition established principles of organised population-based screening and stimulated numerous pilot projects. second multidisciplinary was published 2008 comprises approximately 250 pages divided into seven chapters prepared by 48 authors contributors. Considerable attention has devoted to organised, programme policies which minimise adverse effects maximise...
Given the strong etiologic link between high-risk HPV infection and cervical cancer testing is now being considered as an alternative for cytology-based screening. Many test systems have been developed that can detect broad spectrum of hrHPV types in one assay. However, screening purposes detection not inherently useful unless it informative presence high-grade intraepithelial neoplasia (CIN 2/3) or cancer. Candidate tests to be used should reach optimal balance clinical sensitivity...
An inverse relationship between age and human papillomavirus (HPV) prevalence has been reported in many developed countries, but information on this is scarce other parts of the world. We carried out a cross-sectional study sexually active women from general population 15 areas 4 continents. Similar standardised protocols for women's enrolment, cervical specimen collection PCR-based assays HPV testing were used. different groups was compared by area. 18,498 aged 15-74 years included....
In the first recruitment phase of a randomized trial cervical cancer screening methods (New Technologies for Cervical Cancer Screening [NTCC] study), we compared with conventional cytology by human papillomavirus (HPV) testing in combination liquid-based cytology. HPV-positive women were directly referred to colposcopy if aged 35 or older; younger, they retested after 1 year. second NTCC, randomly assigned (n = 24661) referral indicated atypical squamous cells undetermined significance more...
In a project coordinated by the International Agency for Research on Cancer (IARC) 31 experts from 11 European countries and IARC have developed supplements to current guidelines quality assurance in cervical cancer screening. The take into account potential of primary testing human papillomavirus (HPV) vaccination against HPV infection improve prevention control will be published Commission book format. They include 62 recommendations or conclusions which strength evidence respective is...
The second report on the implementation status of cancer screening in European Union (EU) was published 2017. described status, protocols and organization (updated till 2016) invitation coverage (for index year 2013) breast, cervical colorectal EU. Experts programme monitoring ( N = 80) from EU Member States having access to requisite information their respective countries provided data through online questionnaires. Data collected for performed framework publicly mandated programmes only....
Although testing for human papillomavirus (HPV) has higher sensitivity and lower specificity than cytology alone detecting cervical intraepithelial neoplasia (CIN), studies comparing conventional liquid-based have had conflicting results.In the first phase of a two-phase multicenter randomized controlled trial, women aged 35-60 years in arm (n = 16,658) were screened using cytology, experimental 16,706) tested high-risk HPV types Hybrid Capture 2 assay. Women referred to colposcopy with...
<b>Objective</b> To compare the accuracy of conventional cytology with liquid based for primary screening cervical cancer. <b>Design</b> Randomised controlled trial. <b>Setting</b> Nine programmes in Italy. <b>Participants</b> Women aged 25-60 attending a new round: 22 466 were assigned to arm and 708 experimental arm. <b>Interventions</b> Conventional compared testing human papillomavirus. <b>Main outcome measure</b> Relative sensitivity intraepithelial neoplasia grade 2 or more at blindly...
A questionnaire survey was conducted by the Epidemiology Working Group of European Cervical Cancer Screening Network, and International Agency for Research on Cancer, IARC, between August December 2003 in 35 centres 20 countries with reliable cervical cancer incidence and/or mortality data databanks held at IARC WHO. The completed 28 from countries. final tables included information 25 18 Six had started screening 1960s, whereas 10 or regions least a pilot programme 2003. There were six...
Abstract The CanScreen5 project is a global cancer screening data repository that aims to report the status and performance of breast, cervical colorectal programs using harmonized set criteria indicators. Data collected mainly from Ministry Health in each country underwent quality validation ultimately became publicly available through Web-based portal. Until September 2022, 84 participating countries reported for breast ( n = 57), 75) or 51) repository. Substantial heterogeneity was...